New Buy Rating for Kenvue, Inc KVUE, the Technology Giant

Our committed collaboration fuels our relentless external competitive drive — because the stronger our bonds are, the stronger our brands are, too. Here’s what analysts will be focusing on, and how the stock currently maps against Wall Street estimates. Figure 3 shows that the LOEs ndax review of Xarelto, Opsumit and Edurant could lead to significant sales losses in 2025. Xarelto deserves special mention, as JNJ only markets this highly successful anticoagulant in the U.S. (it was developed jointly with Bayer HealthCare AG, which holds international marketing rights).

1. It expects annual sales growth through 2025 to be about 3% to 4% globally, according to the filing.
2. I present an additional DCF scenario to highlight the downside potential in the stock should Kenvue grow sales at management’s expectation, which is lower than third-party estimates.
3. See which 3 stocks are most likely to make moves following their insider activities.
4. I will offer my opinion on JNJ’s two remaining segments, their future prospects, and the decline in cash flow due to the split-off of the Consumer Health segment, also in light of the ongoing litigation.
5. JNJ’s Innovative Medicine and MedTech segments are similarly well diversified.

It helps, too, that Switzerland has the same commitment to excellence as Germany — exemplified by the country’s global dominance of the watchmaking market, with brands such as Patek Philippe, Rolex and Blancpain. The Consumer Health segment generated revenue of $14.6 billion in Full-Year 2021 and, following the planned separation, Kenvue would generate sales in over 100 countries, driven by world-class innovation capabilities and demonstrated business momentum. It expects annual sales growth through 2025 to be about 3% to 4% globally, according to the filing. Kenvue expects to pay a quarterly cash dividend of about 20 cents per share starting with the third quarter, which ends Oct. 1.

KVUE Stock IPO: When Does Kenvue Go Public? What Is the Kenvue IPO Price Range?

Kenvue’s stock has stumbled following its IPO and separation from healthcare giant Johnson & Johnson. Shares are down more than 20% since it came public, driving its dividend yield up to 3.8%. The company noted it will own 1.7 billion shares of Kenvue’s common stock after the IPO, representing 91.9% of the spinoff’s total shares. Last year, J&J said it will reduce the rest of its stake in Kenvue later in the year.

Toro Energy Limited (ASX: TOE) – Trading Halt

Regulatory compliance is often incredibly complex and in many cases a medical startup might not have the resources to manage it in multiple regions. It also helps that the Nordic countries consistently https://forex-review.net/ rank among the happiest places in the world. In other words, a happier and more educated population means more innovation — and more innovation means more ground-breaking technology.

Iconic brands, extraordinary teams

Band-Aid, for instance, was developed by J&J itself more than 100 years ago, while Tylenol was brought in via an acquisition in 1959. J&J’s biggest move with the group was the 2006 purchase of the Pfizer (PFE) consumer health business, a deal that brought in Rogaine, Rolaids, and Zantac, among other brands. It was also a deal that made consumer health a much more significant part of J&J’s overall sales. Reliable fundamental data to provide unconflicted insights into the fundamentals and valuation of private and public businesses. The European healthcare technology market is among the most innovative in the world.

Kenvue to participate in the Morgan Stanley Global Consumer & Retail Conference on December 6, 2023

Samuel O’Brient has been covering financial markets and analyzing economic policy for three-plus years. His areas of expertise involve electric vehicle (EV) stocks, green energy and NFTs. Paul Ruh, J&J’s chief financial officer of consumer health and a former PepsiCo executive, will become the CFO of Kenvue before the offering is completed.

J&J announced the split in late 2021 as a bid to streamline operations and refocus on its pharmaceutical and medical device divisions. Shares will begin trading Thursday on New York Stock Exchange under the ticker “KVUE.” Proceeds from the offering and any profits from related debt-financing transactions will go to J&J, but Kenvue will retain $1.17 billion in cash and cash equivalents.

The catch, however, is that the trailing figures don’t include any interest expense. (Technically, Kenvue booked $1 million in Q1 2023.) But the debt taken out to fund the J&J payment will start accruing material interest beginning in Q2. Per the prospectus, the nearly $9 billion in gross debt will have a weighted average interest rate of 5.1%. Net of tax savings, that’s a $340 million annual hit to net profit, or about $0.18 per share. With 1.915 billion shares outstanding after the IPO, trailing twelve-month adjusted earnings per share is $1.35. Just above $25, then, KVUE is trading for a seemingly attractive 18.5x earnings.

More information regarding Kenvue, including the company’s board of directors and financial transaction information will be available at a later date. “Unveiling the Kenvue brand is a defining moment for our stakeholders and an important part of the planned separation,” said Thibaut Mongon, CEO Designate, Kenvue, the planned New Consumer Health Company. “We breathe life into some of the world’s most iconic and beloved brands every day, so we harnessed that same expertise, love, and energy into developing our new corporate identity.” The spinoff posted $14.95 billion in sales for 2022 and a net income of $1.46 billion on a pro forma basis, according to a preliminary prospectus filed with the Securities and Exchange Commission last week. Mongon previously served as J&J’s executive vice president and worldwide chair of consumer health.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. All securities issued under the Private Placement are subject to a hold period of four months and one day. Thermage is a non-invasive treatment that uses radiofrequency technology to help tighten and improve the smoothness and texture of the skin’s surface to optimize a patient’s appearance. Thermage is a versatile and effective treatment that can be used on all skin types and genders, on a wide range of areas on the face, body and around the eyes.

Meet Joe Contrino: Proud to be open & out at Kenvue

He noted that very little construction is being done at our sites to install fossil fuel generation. Instead, we are prioritizing and investing in renewable energy, whether it’s solar, wind, hydroelectricity, or geothermal. Just as our company is embedded in all parts of the world, so is our commitment to producing green energy. This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at . This INNSpired article was written according to INN editorial standards to educate investors. Although standards in the EU are generally more stringent, that doesn’t necessarily mean adherence to North American regulations such as the US Food and Drug Administration is easy.

This is by design, however — it is far better for healthcare technology to have to jump through multiple hoops prior to distribution than for it to put a patient’s life at risk. Switzerland, too, has long been at the forefront of innovation across multiple industries. When it comes to Switzerland’s healthcare industry, the country ranked first in the 2022 World Index of Healthcare Innovation for the third year in a row. Switzerland invests twice as much into medical research and development than any other country, and its scientists ranked first globally for publishing highly cited academic research. Along with the name and purpose, Kenvue’s visual identity represents the company’s timelessness, while allowing space for its iconic brands to also have a home. The new logo centers on the “K” symbol, embodying the company’s strengths – the geometry of the rectangle representing scientific precision and the round edges evoking the warmth of care.

This not only generates investment capital for the healthcare technology company but also drives value for shareholders and investors. As with any market, you need to know what to look for if you’re to make smart decisions. Bringing European healthcare technologies to the North American market can potentially improve healthcare in this part of the world, open up new market opportunities for investors and expose those companies to significant growth capital. Today, as the world’s largest and most broadly-based healthcare company, we are committed to using our reach and size for good. With a market cap of over $389 billion, Johnson & Johnson is one of the world’s most valuable companies. It is one of only two U.S.-based companies that has a prime credit rating of AAA.